ReviewLife (Basel, Switzerland)2022
A Review of Biosensors for Detecting Tumor Markers in Breast Cancer.
Review in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 64 citations in OpenAlex.
- Electrochemical Detection of Cancer Biomarkers: From Molecular Sensing to Clinical Translation.Biosensors · 2026Review
- Gene expression profiling and predictive modeling of cancer biomarkers using machine learning and IoT-Enabled biosensors.Scientific reports · 2025Article
- Potential of Serum ApoC1 as a Noninvasive Biomarker for Breast Cancer Detection and Prognosis: A Prospective Case-Control Study.Cancer reports (Hoboken, N.J.) · 2025Article
- Nanomaterials for Theranostic Management of Oral Cancer: Advances in Imaging, Biosensing, Targeted Delivery, and Multimodal Synergistic Therapy.International journal of nanomedicine · 2025Review
- Advances in breast cancer diagnosis: a comprehensive review of imaging, biosensors, and emerging wearable technologies.Frontiers in oncology · 2025Review
- Cancer treatment approaches within the frame of hyperthermia, drug delivery systems, and biosensors: concepts and future potentials.RSC advances · 2024Review
- Feature-based detection of breast cancer using convolutional neural network and feature engineering.Scientific reports · 2024Article
- An electrochemical immunosensor based on MXene-GQD/AuNPs for the detection of trace amounts of CA-125 as specific tracer of ovarian cancer.Mikrochimica acta · 2024Article
- Current Trends of Raman Spectroscopy in Clinic Settings: Opportunities and Challenges.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Label-free electrochemical cancer cell detection leveraging hemoglobin-encapsulated silver nanoclusters and Cu-MOF nanohybrids on a graphene-assisted dual-modal probe.Scientific reports · 2023Article
- Recent Advances in Surface Plasmon Resonance (SPR) Technology for Detecting Ovarian Cancer Biomarkers.Cancers · 2023Review
- Application of Biosensors in Detecting Breast Cancer Metastasis.Sensors (Basel, Switzerland) · 2023Review
- Bibliometric and visualized analysis of applying tumor markers in lung cancer diagnosis from 2000 to 2022.Cancer innovation · 2023Review
- CNT and Graphene-Based Transistor Biosensors for Cancer Detection: A Review.Biomolecules · 2023Review
- Distinguishing Healthy and Carcinoma Cell Cultures Using Fluorescence Spectra Decomposition with a Genetic-Algorithm-Based Code.Biosensors · 2023Article
- Application of Various Optical and Electrochemical Nanobiosensors for Detecting Cancer Antigen 125 (CA-125): A Review.Biosensors · 2023Review
- Recent Progress in Biosensors for Detection of Tumor Biomarkers.Molecules (Basel, Switzerland) · 2022Review
- A Review of Transition Metal Dichalcogenides-Based Biosensors.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Breast cancer has the highest cancer incidence rate in women. Early screening of breast cancer can effectively improve the treatment effect of patients. However, the main diagnostic techniques available for the detection of breast cancer require the corresponding equipment, professional practitioners, and expert analysis, and the detection cost is high. Tumor markers are a kind of active substance that can indicate the existence and growth of the tumor. The detection of tumor markers can effectively assist the diagnosis and treatment of breast cancer. The conventional detection methods of tumor markers have some shortcomings, such as insufficient sensitivity, expensive equipment, and complicated operations. Compared with these methods, biosensors have the advantages of high sensitivity, simple operation, low equipment cost, and can quantitatively detect all kinds of tumor markers. This review summarizes the biosensors (2013-2021) for the detection of breast cancer biomarkers. Firstly, the various reported tumor markers of breast cancer are introduced. Then, the development of biosensors designed for the sensitive, stable, and selective recognition of breast cancer biomarkers was systematically discussed, with special attention to the main clinical biomarkers, such as human epidermal growth factor receptor-2 (HER2) and estrogen receptor (ER). Finally, the opportunities and challenges of developing efficient biosensors in breast cancer diagnosis and treatment are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.